- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04101669
The RESET System Pivotal Clinical Trial (Protocol Revision K) (STEP-1)
Une étude randomisée, multicentrique et pivot d'efficacité et d'innocuité évaluant le système EndoBarrier® pour l'amélioration de la glycémie chez les patients atteints de diabète de type 2 et d'obésité insuffisamment contrôlés
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study.
A multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and effectiveness of the RESET System plus moderate intensity lifestyle and dietary counseling compliant with 2024 ADA Standard of Care as compared to a sham control receiving moderate intensity lifestyle and dietary counseling. Both the treatment and sham group will practice medical management compliant with STEP-1 Study Guidelines. Patients will be randomized 3 (RESET):1 (Sham).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The objective of this study is to evaluate the safety and effectiveness of the RESET System when used with moderate intensity lifestyle and dietary counseling and medical management, in patients with baseline HbA1c ≥ 7.5% and ≤10%, and BMI ≥ 30 kg/m2 and ≤ 50kg/m2, whose diabetes medications consist of at least dual therapy for 3 months, yet have not achieved adequate HbA1c control (<7.5%).
Specific objectives of this study are:
- To determine if the RESET System significantly improves glycemic control
- To determine that the RESET System can be safely used to improve glycemic control
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Aoife Devery, MA
- Numéro de téléphone: 617.528.8880
- E-mail: adevery@morphicmed.com
Sauvegarde des contacts de l'étude
- Nom: Lina Ginneti, BS
- Numéro de téléphone: 617.216.6699
- E-mail: lginnetti@morphicmed.com
Lieux d'étude
-
-
Arizona
-
Gilbert, Arizona, États-Unis, 85234
- Recrutement
- Banner Health
-
Chercheur principal:
- Neil Sharma, MD
-
Contact:
- Bethany Kerr
- Numéro de téléphone: (480) 649-6600
- E-mail: Bethany.Kerr2@bannerhealth.com
-
Tucson, Arizona, États-Unis, 85710
- Recrutement
- M3 Wake Research
-
Contact:
- Namrata Oza
- Numéro de téléphone: 520-230-1372
- E-mail: noza@wakeresearch.com
-
Chercheur principal:
- David Alster, MD
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20010
- Recrutement
- MedStar Health Research Institute
-
Chercheur principal:
- John Brebbia, MD
-
Contact:
- Temesgen Atew
- Numéro de téléphone: 202-877-5819
- E-mail: Temesgen.A.Atew@medstar.net
-
-
Florida
-
Boynton Beach, Florida, États-Unis, 33435
- Recrutement
- Imagine Research
-
Chercheur principal:
- Aaron Cohen, MD
-
Contact:
- Zachary M Weiss
- E-mail: Zachary@imagineresearch.com
-
Miami, Florida, États-Unis, 33140
- Recrutement
- HCA Health Research Institute
-
Contact:
- Ana Portela
- Numéro de téléphone: 786-457-7672
- E-mail: ana.portela@hcahealthcare.com
-
Chercheur principal:
- Nestor De La Cruz, MD
-
Miami, Florida, États-Unis, 33143
- Recrutement
- UMiami
-
Contact:
- Giana Ilarraza
- Numéro de téléphone: 305-689-1910
- E-mail: gni4@med.miami.edu
-
Chercheur principal:
- Robert Cubas
-
Miami Beach, Florida, États-Unis, 33140
- Recrutement
- Quantum Clinical Trials
-
Chercheur principal:
- George Azar, MD
-
Contact:
- Nicole Burgos
- Numéro de téléphone: 955-375-2235
- E-mail: nicole@qctrials.com
-
Orange City, Florida, États-Unis, 32763
- Recrutement
- Optimal Research Sites
-
Contact:
- Claxton Copeland
- Numéro de téléphone: (386) 218-5911
- E-mail: claxton.copeland@optimalresearchsites.net
-
Chercheur principal:
- Kristyna Paradis, MD
-
Orlando, Florida, États-Unis, 32806
- Recrutement
- Orlando Health
-
Contact:
- Leticia Morales
- Numéro de téléphone: 321-843-8910
- E-mail: Leticia.Morales@orlandohealth.com
-
Chercheur principal:
- Andre Texeira, MD
-
Plant City, Florida, États-Unis, 33563
- Recrutement
- Denali Health Plant City
-
Contact:
- Maryam Bintumar
- Numéro de téléphone: (217) 933-2108
- E-mail: maryam.bintumar@orlandohealth.com
-
Chercheur principal:
- Luis Aponte, MD
-
Pompano Beach, Florida, États-Unis, 33060
- Recrutement
- Clinical Research Center of Florida
-
Chercheur principal:
- Howard Koch, MD
-
Contact:
- Cassandra Bravo
- Numéro de téléphone: 954-372-2209
- E-mail: cassandra@floridacrc.com
-
West Palm Beach, Florida, États-Unis, 33407
- Pas encore de recrutement
- Health Synergy Clinical Research
-
Chercheur principal:
- Robert Dudley, MD
-
Contact:
- Michael Maresca
- E-mail: mmaresca@hscresearch.com
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30083
- Recrutement
- Denali Health Atlanta
-
Contact:
- Maria Johnson
-
Contact:
- Maryam Bintumar
- Numéro de téléphone: (404) 999-2734
- E-mail: maryam@denali-health.com
-
Marietta, Georgia, États-Unis, 30060
- Recrutement
- Drug Studies America
-
Contact:
- Tanya Astorga
- Numéro de téléphone: 470-535-9379
- E-mail: tastorga@drugstudies.net
-
Chercheur principal:
- Glenn Gatipon, MD
-
Snellville, Georgia, États-Unis, 30078
- Recrutement
- EBGS Clinical Research
-
Chercheur principal:
- Aliu Sanni, MD
-
Contact:
- Cheyenne Head
- E-mail: cheyenne@esbariatricandgeneralsurgery.com
-
-
Louisiana
-
Lake Charles, Louisiana, États-Unis, 70605
- Recrutement
- Elevate Clinical Research, Lake Charles
-
Contact:
- Ashley Pennington
- Numéro de téléphone: 4693401433
- E-mail: ashley.pennington@elevateclinical.com
-
Chercheur principal:
- Francisco Marrero, MD
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Recrutement
- Brigham and Women's Hospital
-
Chercheur principal:
- Christopher C Thompson, MD
-
Contact:
- Delaney Mahan, MS
- Numéro de téléphone: 617-525-8266
- E-mail: dmanahan@bwh.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- Recrutement
- Michigan Medicine, Division of Gastroenterology and Hepatology
-
Chercheur principal:
- Allison R Schulman, MD
-
Contact:
- Spring Stonebraker
- Numéro de téléphone: 734-615-6258
- E-mail: sprstone@med.umich.edu
-
-
Minnesota
-
Rochester, Minnesota, États-Unis, 55905
- Recrutement
- Mayo Clinic
-
Contact:
- Abigail Stromme
- Numéro de téléphone: (507) 284-2511
- E-mail: Stromme.Abigail@mayo.edu
-
Chercheur principal:
- Dan Maselli, MD
-
-
New York
-
New York, New York, États-Unis, 10021
- Recrutement
- Weill Cornell Medicine
-
Chercheur principal:
- Reem Sharaiha, MD
-
Contact:
- Veronika Solomon
- E-mail: ves4012@med.cornell.edu
-
-
Texas
-
Atascocita, Texas, États-Unis, 77346
- Recrutement
- Elevate Clinical Research, Atascocita
-
Contact:
- Shalina Wells
- Numéro de téléphone: 4693401433
- E-mail: Shalina.Wells@elevateclinical.com
-
Chercheur principal:
- Maria Berdayes, MD
-
Dallas, Texas, États-Unis, 75224
- Recrutement
- M3 Wake Research
-
Contact:
- Vicki Martinez
- E-mail: vmartinez@wakeresearch.com
-
Chercheur principal:
- Carlos Arauz-Pacheco, MD
-
DeSoto, Texas, États-Unis, 75115
- Recrutement
- Epic Medical Research
-
Chercheur principal:
- Haresh Boghara, MD
-
Contact:
- Josie Propheter
- Numéro de téléphone: 9302324376
- E-mail: jquemado@epicmedresearch.com
-
Forney, Texas, États-Unis, 75126
- Recrutement
- Care United Research
-
Contact:
- Caroline Woodruff
- Numéro de téléphone: 972-564-0044
- E-mail: caroline.woodruff@careunitedresearch.com
-
Chercheur principal:
- Shilpi Mittal, MD
-
Houston, Texas, États-Unis, 77030
- Recrutement
- Baylor College of Medicine
-
Chercheur principal:
- Wasif M Abidi, MD
-
Contact:
- Haydee Rochits
- Numéro de téléphone: 713-798-0950
- E-mail: BCM-RESET@bcm.edu
-
Houston, Texas, États-Unis, 78504
- Recrutement
- Elevate Clinical Research, Houston
-
Chercheur principal:
- Joe Pouzar, MD
-
Contact:
- Jennifer Keane
- Numéro de téléphone: (832) 240-9765
- E-mail: jennifer.keane@elevateclinical.com
-
Prosper, Texas, États-Unis, 75078
- Recrutement
- VAST Clinical Research
-
Contact:
- Bukola Adaramola
- E-mail: bukolaa@vastclinicalresearch.com
-
Chercheur principal:
- Uchenna Ozuah
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age ≥22 years and ≤ 65 years
- Have understood and signed the approved informed consent form
- Diagnosis of type 2 diabetes
- HbA1c ≥ 7.5% and ≤10%
- BMI ≥30kg/m2 and ≤ 50kg/m2
- Willing and able to comply with study requirements
- Documented negative pregnancy test in women of childbearing potential
- Women of childbearing potential not intending to become pregnant (continue to be on an approved form of birth control) for the duration of their trial participation, including post explant period. Women of child-bearing age without known sterilization will be placed on 1 form of birth-control to prevent unwanted pregnancies
- At least one year of medical records available, including detailed medical therapy and dosing information
- Failed to achieve adequate HbA1c reduction (<7.5%) after dual therapy for at least 3-month stable dosage of diabetes medication(s), including insulin, metformin, SGLT-2 inhibitor, GLP-1 RA, Dual GLP-1/GIPR agonist or, other medications including meglitinides, sulfonylureas, thiazolidinediones, or DPP-4s.
Exclusion Criteria:
- Previous treatment with the RESET System
- Previous GI surgery that could preclude the ability to place the RESET Liner or affect the function of the RESET Liner, or abnormal GI anatomical finding that could preclude the ability to place the RESET Liner or affect the function of the RESET Liner
- Hypoglycemia and/or DKA/HHNK in the last 6 months requiring 3rd party assistance.
- Known history of liver disease (e.g., viral or autoimmune etiology, METAVIR grade 2 or higher fibrosis/cirrhosis from a biopsy within the past 6 months, but not including incidental fatty liver)
- eGFR of less than 45 ml/min/1.73 m2
- Prior history of an abscess requiring hospitalization, intravenous antibiotics or drainage
- Previous treatment for severe liver disease and/or biliary tract disease, including but not limited to, surgery, bile duct dilatation, and stent placement
- Diagnosis of type 1 diabetes mellitus or having any history of ketoacidosis
- Fasting C-peptide < 1.0 ng/mL
- Triglyceride level > 600 mg/dL
- Vitamin D deficiency (<20ng/ml)
- Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000/microliter, or known coagulopathy
- Height < 5 feet (152.4 cm)
- Current alcohol addiction, current drug addiction or usage, of drugs such as, narcotics, opiates, or benzodiazepines and other addictive tranquilizers
- History of pancreatitis, including gallstone related pancreatitis (subsequent to which patient has cholecystectomy)
- Diagnosis of osteopenia or osteoporosis or currently taking denosumab, romosozumab-aqqg, bisphosphonates or teriparatide
- Diagnosis of autoimmune connective tissue disorder (e.g. lupus erythematosus, scleroderma)
- Active or recent (less than 12 months) gastroesophageal reflux disease (GERD), unless treated with H2Ras not PPI.
- Uncontrolled thyroid disease, including a history of thyroid cancer, hyperthyroidism, or taking thyroid hormone for any reason other than primary hypothyroidism (TSH level must be between 0.4-4)
- Currently taking prescription antithrombotic therapy (e.g. anticoagulant or antiplatelet agent) within 10 days prior to randomization and/or there is a need or expected need to use during the trial 9 months post implant procedure
- Currently taking the following medications (within 30 days prior to randomization) and/or there is a need or expected need to use these medications during the trial 12 months post index procedure: Restricted Medications/Supplements Systemic corticosteroids Proton Pump Inhibitor (PPI) Drugs known to affect GI motility (e.g.metoclopramide) Prescription or over-the-counter weight loss medication(s) Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), aspirin, ibuprofen, and other anti-inflammatory medication for study duration Medications known to cause significant weight gain or weight loss (e.g. chemotherapeutics) Supplements that are known or suspected to increase bleeding risk including but not limited to: Gingko biloba Ginseng Vitamins C & E Turmeric St. John's wort Evening primrose oil Feverfew Green Tea Extract
- Active H. pylori
- History of Crohn's disease, atresias or untreated stenoses
- Abnormal pathologies or conditions of the gastrointestinal tract, including ulcers or upper gastrointestinal bleeding conditions within 3 months of randomization
- Patients may be disqualified for study inclusion for any condition determined by the PI that places patient at undue risk.
- Poor dentition not allowing complete chewing of food
- Enrolled in another investigational study within 3 months of screening for this study (enrollment in observational studies is permitted)
- Residing in a location without ready access to study site medical resources
- Documented weight loss of 5% total body weight (TBW) anytime during the 3 months preceding randomization
- Positive Fecal Immunochemical Test (FIT)
- History or observation of psychological disorder or behavior which could preclude compliance to the treatment and follow up plan
- No access to an active telephone and internet service for provision of Follow Up Schedule calls and electronic diary
- Having donated blood or received a blood transfusion in the 90 days prior to baseline labs. Patients should agree not to donate blood during the study
- Any condition that increases red cell turnover, such as thalassemia
- Existence of (>5 cm string test) Pseudomonas aeruginosa, Stenotrophomonas maltophilia and/or Klebsiella pneumoniae serotype K1 and K36. A known sensitivity to nickel or titanium
37. Do not meet the screening criteria for Fibroscan (i.e., Fibroscan unsafe, or Fibroscan conditional but not appropriate for the region of interest 38. History of myocardial infarction, stroke, or hospitalization for heart failure 39. History Afib and/or cardiac arrythmias 40. History of unstable angina 41.History of new or worsening signs or symptoms of CAD within the last 3 months 42.Any contraindication to general anesthesia or high risk for general anesthesia as determined by anesthesiologist (e.g., ASA score 4 or higher)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: RESET Treatment Arm
Patients in ARM 1, will receive an upper endoscopy and will be treated with the RESET Liner |
The RESET System is provided as a single-use, sterile device and consists of an RESET Liner preloaded, packaged and sterilized within the RESET Delivery System. The RESET Delivery System is utilized to deliver the RESET Liner to the proximal small intestine. The RESET Liner is removed using the RESET Retrieval System. The RESET System incorporates no pharmacological, biological tissue or blood products.
Autres noms:
|
|
Comparateur factice: Sham Control Arm
Patients in Arm 2 will receive an upper endoscopy, but will not be treated with the RESET Liner. |
Patient receives upper endoscopy but no treatment |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in HbA1c
Délai: 9 Months
|
Change in HbA1c value from baseline to 9 months. |
9 Months
|
|
SAE Rate
Délai: 9 months
|
Incidence of serious adverse events |
9 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
HbA1c Reduction
Délai: 9 and 21 months
|
Proportion of patients who achieve an HbA1c reduction ≥0.5% |
9 and 21 months
|
|
Weight Loss
Délai: 9 and 21 months
|
Proportion of patients who achieve percent total body weight loss ≥ 5% from baseline |
9 and 21 months
|
|
Insulin use
Délai: 9 and 21 months
|
Reduction in percentage insulin units per day |
9 and 21 months
|
|
Fasting blood glucose level
Délai: 9 and 21 months
|
Reduction in fasting blood glucose values |
9 and 21 months
|
|
Diabetes Treatment Satisfaction Questionnaire
Délai: 9 and 21 months
|
Change from baseline in treatment satisfaction using Diabetes Treatment Satisfaction Questionnaire (DTSQ) (0-6, 0=Very dissatified, 6=Very satisfied) |
9 and 21 months
|
|
Impact of Weight on Quality of Life
Délai: 9 and 21 months
|
Impact of weight on quality of life (IWQOL) questionnaire change from baseline (0-100, 0=Worst, 100=Best quality of life) |
9 and 21 months
|
|
EQ-5D
Délai: 9 and 21 months
|
Change from baseline in treatment satisfaction using EuroQol-5D (1-5, 1=No problem, 5=Extreme problems) |
9 and 21 months
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
% HbA1c reduction
Délai: 9 and 21 months
|
Proportion of patients who achieve an HbA1c reduction of ≥0.5%, ≥1%, ≥1.5% and ≥2% |
9 and 21 months
|
|
Total Body Weight
Délai: 9 and 21 months
|
Proportion of patients who achieve a % total body weight loss of ≥5%, ≥10%, and ≥15% |
9 and 21 months
|
|
Insulin Units
Délai: 9 and 21 months
|
Proportion of patients who achieve a reduction in total number of insulin units per day of ≥25%, ≥50%, ≥75% and ≥100% |
9 and 21 months
|
|
HbA1c Value
Délai: 9 and 21 months
|
Proportion of patients who achieve an HbA1c of <7% |
9 and 21 months
|
|
Insulin Dosage
Délai: 9 and 21 months
|
Proportion of patients reducing insulin dosage |
9 and 21 months
|
|
Non-insulin Medication use
Délai: 9 and 21 months
|
Proportion of patients reducing dosage of non-insulin diabetes medications |
9 and 21 months
|
|
Cholesterol
Délai: 9 and 21 months
|
Reduction in LDL cholesterol |
9 and 21 months
|
|
Triglycerides
Délai: 9 and 21 months
|
Reduction in triglycerides |
9 and 21 months
|
|
Blood Pressure
Délai: 9 and 21 months
|
Reduction in systolic blood pressure values |
9 and 21 months
|
|
Vitamin D Levels
Délai: 9 and 21 months
|
Changes in vitamin D levels |
9 and 21 months
|
|
Vitamin D Supplementation
Délai: 9 and 21 months
|
Average vitamin D supplementation levels required to maintain normal vitamin D levels |
9 and 21 months
|
|
Vitamin D Refraction
Délai: 9 and 21 months
|
Proportion of patients refractory to vitamin D supplementation |
9 and 21 months
|
|
Serum Creatinine
Délai: 9 and 21 months
|
Change in serum creatinine levels |
9 and 21 months
|
|
eGFR
Délai: 9 and 21 months
|
Change in eGFR levels |
9 and 21 months
|
|
Serum Creatinine Levels
Délai: 9 and 21 months
|
Proportion of patients with doubling of serum creatinine levels |
9 and 21 months
|
|
MAFLD - Fatty Liver
Délai: 9 and 21 months
|
Absolute and magnitude reductions in hepatic fat fraction |
9 and 21 months
|
|
MASH - Liver Stiffness
Délai: 9 and 21 months
|
Reduction in liver stiffness |
9 and 21 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Christopher C Thompson, MD, Brigham and Women's Hospital
Publications et liens utiles
Publications générales
- Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89. doi: 10.1056/NEJMoa0806470. Epub 2008 Sep 10.
- Torquati A, Lutfi R, Abumrad N, Richards WO. Is Roux-en-Y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients? J Gastrointest Surg. 2005 Nov;9(8):1112-6; discussion 1117-8. doi: 10.1016/j.gassur.2005.07.016.
- Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 Aug 12;321(7258):405-12. doi: 10.1136/bmj.321.7258.405.
- Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006 Dec;29(12):2632-7. doi: 10.2337/dc06-0703.
- Koh-Banerjee P, Wang Y, Hu FB, Spiegelman D, Willett WC, Rimm EB. Changes in body weight and body fat distribution as risk factors for clinical diabetes in US men. Am J Epidemiol. 2004 Jun 15;159(12):1150-9. doi: 10.1093/aje/kwh167.
- Ford ES, Li C, Little RR, Mokdad AH. Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Diabetes Care. 2008 Jan;31(1):102-4. doi: 10.2337/dc07-0565. Epub 2007 Oct 12. No abstract available.
- Detournay B, Cros S, Charbonnel B, Grimaldi A, Liard F, Cogneau J, Fagnani F, Eschwege E. Managing type 2 diabetes in France: the ECODIA survey. Diabetes Metab. 2000 Nov;26(5):363-9.
- Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003 Jan 1;289(1):76-9. doi: 10.1001/jama.289.1.76.
- Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg. 2002 Nov;236(5):554-9. doi: 10.1097/00000658-200211000-00003.
- Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995 Apr 1;122(7):481-6. doi: 10.7326/0003-4819-122-7-199504010-00001.
- Ritz E. Limitations and future treatment options in type 2 diabetes with renal impairment. Diabetes Care. 2011 May;34 Suppl 2(Suppl 2):S330-4. doi: 10.2337/dc11-s242. No abstract available.
- Brethauer SA, Chang J, Galvao Neto M, Greve JW. Gastrointestinal devices for the treatment of type 2 diabetes. Surg Obes Relat Dis. 2016 Jul;12(6):1256-61. doi: 10.1016/j.soard.2016.02.031. Epub 2016 Mar 2.
- Frattini F, Borroni G, Lavazza M, Liu X, Kim HY, Liu R, Anuwong A, Rausei S, Dionigi G. New endoscopic procedures for diabetes mellitus type 2 and obesity treatment. Gland Surg. 2016 Oct;5(5):458-464. doi: 10.21037/gs.2016.10.03.
- Laubner K, Riedel N, Fink K, Holl RW, Welp R, Kempe HP, Lautenbach A, Schlensak M, Stengel R, Eberl T, Dederichs F, Schwacha H, Seufert J, Aberle J. Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study. Diabetes Obes Metab. 2018 Aug;20(8):1868-1877. doi: 10.1111/dom.13300. Epub 2018 Apr 23.
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854-65.
- Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther. 2009 Jun;11 Suppl 1:S55-67. doi: 10.1089/dia.2008.0132.
- Bennett MC, Badillo R, Sullivan S. Endoscopic Management. Gastroenterol Clin North Am. 2016 Dec;45(4):673-688. doi: 10.1016/j.gtc.2016.07.005.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système endocrinien
- Troubles nutritionnels
- Maladies métaboliques
- Suralimentation
- Poids
- Troubles du métabolisme du glucose
- Diabète sucré
- En surpoids
- Conditions pathologiques, signes et symptômes
- Maladies nutritionnelles et métaboliques
- Signes et symptômes
- Obésité
- Diabète sucré, Type 2
- acide salicylhydroxamique
Autres numéros d'identification d'étude
- 18-1
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .